Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis

Mykoniatis, Ioannis; Tsiakaras, Stavros; Samarinas, Michael; Anastasiadis, Anastasios; Symeonidis, Evangelos N.; Sountoulides, Petros

doi:10.2147/btt.s290286

Cited by 4 publications

(3 citation statements)

References 65 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a humanized monoclonal antibody against NGF, tanezumab has a high affinity and specificity for bonding with NGF, thus blocking the mediator from engaging with nociceptive nerve cell receptors. The latter comprises the high- and low-affinity receptors, tropomyosin-related kinase A and p75 [ 32 ]. Following the use of tanezumab, a clinical trial reported an improvement in pain scores as well as enhanced function and overall evaluation outcomes in individuals with chronic painful disorders, not including IC [ 33 – 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, mixed data regarding its efficacy in comparison with a placebo have been presented. In patients with osteoarthritic symptoms, fulranumab demonstrated greater efficacy than an opiate, although, in low back pain, no benefit over a placebo was seen [ 32 ]. A study by Wang et al [ 37 ] failed to show any positive effects from one dose, but the sample size was restricted and the study had insufficient statistical power.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis

Park,

Kim,

Lee

et al. 2024

BMC Urol

View full text Add to dashboard Cite

Background Despite the publication of several meta-analyses regarding the efficacy of certain therapies in helping individuals with interstitial cystitis (IC) / bladder pain syndrome (BPS), these have not provided a comprehensive review of therapeutic strategies. The study aimed to determine the efficacy of various therapies for IC/BPS and identify potential moderating factors using randomized controlled trials (RCTs). Methods We queried the PubMed, Cochrane, and Embase databases to identify prospective RCTs using inclusion criteria: 1) patients diagnosed with IC, 2) interventions included relevant treatments, 3) comparisons were a specified control or placebo, 4) outcomes were mean differences for individual symptoms and structured questionnaires. The pairwise meta-analysis and network meta-analysis (NMA) were performed to compare the treatments used in IC/BPS. Hedges’ g standardized mean differences (SMDs) were used for improvement in all outcomes using random-effects models. Efficacy outcomes included individual symptoms such as pain, frequency, urgency, and nocturia, as well as structured questionnaires measuring IC/BPS symptoms. Results A comprehensive literature search was conducted which identified 70 RCTs with 3,651 patients. The analysis revealed that certain treatments, such as instillation and intravesical injection, showed statistically significant improvements in pain and urgency compared to control or placebo groups in traditional pairwise meta-analysis. However, no specific treatment demonstrated significant improvement in all outcomes measured in the NMA. The results of moderator analyses to explore influential variables indicated that increasing age was associated with increased nocturia, while longer follow-up periods were associated with decreased frequency. Conclusion This systematic review and meta-analysis provide insights into the efficacy of various treatments for IC. Current research suggests that a combination of therapies may have a positive clinical outcome for patients with IC, despite the fact that treatment for this condition is not straightforward. Trial registration PROSPERO CRD42022384024

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis

Park,

Kim,

Lee

et al. 2024

BMC Urol

View full text Add to dashboard Cite

show abstract

“…New and interesting therapeutic strategies involve combined approaches that include dietary modifications along with botulinum toxin injections or intravesical instillations of hyaluronic acid [ 11 ]. Additionally, the use of immunomodulatory compounds represents a new area of interest [ 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Intravesical Instillations of Hyaluronic Acid as First-Line Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome: Use, Efficacy and Effects on Quality of Life

Plotti,

Cundari,

Ficarola

et al. 2024

Healthcare

View full text Add to dashboard Cite

The efficacy of hyaluronic acid instillations as therapy for patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) has been demonstrated in some clinical studies, with response rates up to 70%. The aim of the study is to investigate the change in symptoms and quality of life in female patients with IC/BPS after intravesical instillations of hyaluronic acid used as first-line treatment. A retrospective single-center cohort study was conducted. Female patients, whose symptoms were compatible with the diagnosis of IC/BPS as defined by the International Continence Society, were treated with a variable number of intravesical instillations of a hyaluronic acid-based drug. Three validated questionnaires were administered by telephone to all patients, before the beginning of the treatment and 6 months after the last administration of the drug. A total of 50 patients with symptoms compatible with the diagnosis of IC/BPS were included in the study. The median number of instillations performed is 4. For all questionnaires, the median value was significantly reduced following treatment with intravesical instillations (p = 0.000). The present study has shown that intravesical hyaluronic acid treatment results in both statistically and clinically significant symptomatic improvement, thereby improving the quality of life of patients with IC/BPS.

show abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS)

Vahlensieck

2023

Urologie

View full text Add to dashboard Cite

Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis

Cited by 4 publications

References 65 publications

Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis

Current updates relating to treatment for interstitial cystitis/bladder pain syndrome: systematic review and network meta-analysis

Intravesical Instillations of Hyaluronic Acid as First-Line Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome: Use, Efficacy and Effects on Quality of Life

Interstitial cystitis/bladder pain syndrome (IC/BPS)

Contact Info

Product

Resources

About